(APOP), Quotes and News Summary


Cellect Biotechnology Ltd is a specialty pharmaceutical company for developing therapeutic products for the treatment of rare and orphan diseases. Its lead product, QRX003, is under development for the treatment of Netherton Syndrome, a rare hereditary skin disease. Its pipeline also includes potential treatments for other rare diseases including Peeling skin syndrome, SAM Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa.

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target